Brief: Ceapro Announces Positive Data From Bioavailability Studies Evaluating Coq10 Formulations Impregnated With Pgx-Processed Carriers
13/10/2022 13:42
Oct 13 (Reuters) - Ceapro Inc CZO.V :
* CEAPRO INC. ANNOUNCES POSITIVE DATA FROM BIOAVAILABILITY
STUDIES
EVALUATING COQ10 FORMULATIONS IMPREGNATED WITH PGX-PROCESSED
CARRIERS
Source text for Eikon: ID:nGNX8yqVnC
Further company coverage: CZO.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ceapro
See all newsBrief: Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
Brief: Ceapro Receives Final Court Approval For Merger With Aeterna Zentaris
Brief: Aeterna Zentaris And Ceapro Announce Merger Of Equals To Create Diversified Biopharmaceutical Company
Brief: Ceapro Inc. Reports 2023 Third Quarter And Nine-Month Financial Results And Operational Highlights
Brief: Ceapro Initiates Phase 1-2A Study Assessing Avenanthramides For Potential Applications In Inflammation Based Diseases